Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells

scientific article published on 22 August 2019

Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41374-019-0307-9
P698PubMed publication ID31439892

P2093author name stringNa Chen
Bing Liu
Jing Cui
Jingyuan Song
Hetian Lei
Jingxiang Zhong
Haote Han
Joanne Aiko Matsubara
Zhengping Hu
P2860cites workInteraction between the retinoblastoma protein and the oncoprotein MDM2Q24323385
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eyeQ24625311
Clinical Overview of MDM2/X-Targeted TherapiesQ26767402
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2Q27642888
MDM2--master regulator of the p53 tumor suppressor proteinQ28138926
Genome editing. The new frontier of genome engineering with CRISPR-Cas9Q28252298
Amplification of a gene encoding a p53-associated protein in human sarcomasQ28270924
RNA-guided gene activation by CRISPR-Cas9-based transcription factorsQ28295458
p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseasesQ28611425
CRISPR-Cas systems for editing, regulating and targeting genomesQ29615781
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expressionQ29615784
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Q29615851
Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.Q30356570
Novel sequential ChIP and simplified basic ChIP protocols for promoter co-occupancy and target gene identification in human embryonic stem cellsQ33475969
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancerQ33559621
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesisQ33601591
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressorQ34030117
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathyQ34429965
Proliferative vitreoretinopathy: risk factors and pathobiologyQ34572836
Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRβ, PI3K/Akt and MAPK pathwaysQ34607101
Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathologyQ34724376
The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathyQ35070151
Nutlin-3-induced redistribution of chromatin-bound IFI16 in human hepatocellular carcinoma cells in vitro is associated with p53 activationQ35080124
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9Q35820051
A novel function of p53: a gatekeeper of retinal detachmentQ36204186
Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elementsQ36338669
Vascular Endothelial Cell Growth Factor A Acts via Platelet-Derived Growth Factor Receptor α To Promote Viability of Cells Enduring Hypoxia.Q37224171
Proliferative vitreoretinopathy: pathobiology and therapeutic targetsQ37448440
Editing VEGFR2 Blocks VEGF-Induced Activation of Akt and Tube FormationQ37682513
The retinal pigment epithelium: an important player of retinal disorders and regenerationQ38123624
Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.Q38710594
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.Q38749151
The Role of MDM2 Amplification and Overexpression in TumorigenesisQ38837916
The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of CellsQ39720539
Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative VitreoretinopathyQ42380716
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndromeQ42734774
Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical studyQ46869907
Role of epithelial-mesenchymal transition in proliferative vitreoretinopathy.Q52666368
β-arrestin1-medieated inhibition of FOXO3a contributes to prostate cancer cell growth in vitro and in vivo.Q55319952
MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent MannerQ56565980
Dependence of artesunate on long noncoding RNA-RP11 to inhibit epithelial-mesenchymal transition of hepatocellular carcinomaQ58597865
Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11Q73167697
Proliferative vitreoretinopathy: an overviewQ77144020
LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradationQ89094868
The pathophysiology of proliferative vitreoretinopathy in its managementQ93588666
P433issue12
P921main subjectCas9Q16965677
P304page(s)1874-1886
P577publication date2019-08-22
P1433published inLaboratory InvestigationQ6467260
P1476titleBlockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells
P478volume99

Reverse relations

Q89902210Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and reviewcites workP2860

Search more.